Feasibility Study of HIPEC for Patients With Stage III or Only Pleural Stage IV Ovarian Carcinoma in First Line Therapy

Feasibility Study of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Patients With Stage III or Only Pleural Stage IV Ovarian Carcinoma in First Line Therapy

Status

Completed

Phases

Phase 1Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01709487

Enrollment

Registered

2012-10-18

Start date

2010-05-31

Completion date

2015-10-31

Last updated

2016-02-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Fallopian Tube Carcinoma, Ovarian Carcinoma, Primary Peritoneal Carcinoma

Keywords

HIPEC, ovarian carcinoma, Bordet

Brief summary

First line treatment for advanced ovarian carcinoma hyperthermic intraperitoneal chemotherapy (HIPEC) after optimal debulking.

Detailed description

Addition of HIPEC to the standard first line treatment of ovarian carcinoma.

Interventions

PROCEDUREHIPEC

HIPEC with cisplatin 50 mg/m2 intraperitoneally at the end of surgery

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

FEMALE

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* stage III or only pleural stage IV ovarian carcinoma first line treatment

Exclusion criteria

* incomplete surgery poor performance status bad general condition

Design outcomes

Primary

Measure	Time frame	Description
mortality rate	24 weeks	We will record the mortality rate of our interventions: 3 cycles of pre-operative chemotherapy, surgery and HIPEC, 3 cycles of post-operative chemotherapy.

Secondary

Measure	Time frame
progression free survival	3 years
Overall survival	3 years

Countries

Belgium

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026